Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Rong GuoDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan 430022, China.ORCID 0000-0003-0000-2543
Shaowen YangDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan 430022, China.ORCID 0009-0008-8694-7495
Yu GaoDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan 430022, China.
Li WenDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan 430022, China.
Hao WangDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan 430022, China.
Yuan FengDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan 430022, China.ORCID 0009-0002-2796-5761
Sixuan ChengDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan 430022, China.
Wenzhu HuDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan 430022, China.
Wenbo LiDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan 430022, China.
Jian RongDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan 430022, China.ORCID 0000-0002-3960-1669
Hyung-Jun ImDepartment of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea.ORCID 0000-0002-4368-6685
Jianfeng LiuState Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Tianjin Institutes of Health Science, Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, China.ORCID 0000-0003-0541-5072
Xiaoli LanDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan 430022, China.ORCID 0000-0002-7263-7399
Rui AnDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan 430022, China.ORCID 0000-0001-6609-7317
Dawei JiangDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan 430022, China.ORCID 0000-0002-4072-0075
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Pulmonary diseases, including malignancies and chronic airway diseases, pose substantial global health challenges requiring advanced therapies. While extracellular vesicles (EVs) show promise as natural delivery vectors, their clinical application is limited by hepatic tropism. To date, no rational design for selectively lung-targeted EVs has been developed. Here, we modulate tumor cell-derived medium vesicles (TMVs) with cationic DOTAP lipids to alter their internal charges and tissue tropism. We accurately tracked the biodistribution of TMVs-DOTAP in vivo via highly sensitive positron emission tomography (PET) imaging, which clearly indicates their enhanced lung-targeting specificity. Furthermore, we engineered an EV-based siRNA delivery system (TMVs-DOTAP/siPD-L1), which effectively targets and silences PD-L1 in melanoma lung metastasis, leading to enhanced tumor immune responses. Mechanistic studies revealed the role of the protein corona in determining lung/liver tropism. This study provides a promising strategy for nucleic acid delivery and immunotherapy in pulmonary diseases.
Indexed as
Extracellular VesiclesLipidsLung NeoplasmsPositron-Emission TomographyRNA, Small InterferingAnimalsCell Line, TumorHumansMiceLipidsRNA, Small Interfering
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Helper lipid-engineered extracellular vesicles enable PET imaging-guided pulmonary siRNA delivery to treat lung metastasis. · full record | OpenQuestion